Sign inJoin waitlistJoin the waitlist

Marina Kremyanskaya

Medical Oncology · Icahn School of Medicine at Mount Sinai

Credentials: · · · ·

History

Research

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
Blood · 2019 · 149 citations
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
Blood · 2022 · 122 citations
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
The Lancet Oncology · 2024 · 105 citations

John Mascarenhas
50 papers
Ronald Hoffman
40 papers
Douglas Tremblay
20 papers
RR
Raajit Rampal
15 papers · 2 as a fellow
Ruben Mesa
9 papers
Joseph Tripodi
8 papers
Abdulraheem Yacoub
7 papers
Alla Keyzner
7 papers
Bridget Marcellino
7 papers
Jonathan Feld
7 papers
Aaron Gerds
6 papers
MS
Mohamed Salama
6 papers

Clinical trials

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
Principal investigator · Recruiting · Phase 1
Marina Kremyanskaya
2023–2027
Ruxolitinib in Combination With Autotransplant
Principal investigator · Withdrawn
Marina Kremyanskaya
2015–2016
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Study chair · Recruiting · Phase 2
Icahn School of Medicine at Mount Sinai
2023–2028
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2024–2027